The therapy of relapsed chronic lymphocytic leukemia (CLL) has changed dramatically in the past year with the regulatory approval of idelalisib and ibrutinib, with other therapeutic small molecules likely to become widely available in the next few years. While durable remissions are being seen in many patients with these agents, it is becoming apparent that some patients with high genomic risk disease will relapse. Next generation sequencing in patients as well as in vitro models is affording us the opportunity to understand the biology behind these relapses, which is the first step to designing rational therapies to prevent and treat targeted therapyresistant CLL. These strategies are critical, as these relapses can be very difficult to manage, and a coordinated effort to put these patients on clinical trials will be required to efficiently determine the optimal therapies for these patients. In this review, we will describe mechanisms of resistance, both proven and hypothesized, for idelalisib, ibrutinib, and venetoclax, describe patterns of resistance that have been described with ibrutinib, and discuss potential strategies for management of disease resistant to these drugs as well as potential strategies to prevent resistance.
Introduction
Chronic Lymphocytic Leukemia (CLL) is undergoing an exciting therapeutic transformation.
Prior to 2014, patients with relapsed disease had a generally unfavorable outcome, with standard therapies of chemoimmunotherapy or single agent immunotherapy achieving response rates and progression free survival (PFS) rates inferior to what is seen in the treatment-naïve setting. Stem cell transplantation, still the only known curative therapy, produces durable remissions in about 50% of patients (reviewed in 6 ), but morbidity and mortality in this generally older population remains problematic. However, the introduction and subsequent approval of two oral kinase inhibitors (idelalisib and ibrutinib) have changed the standard of care for patients with relapsed disease. As well, other novel small molecule inhibitors currently in clinical trials have the potential to continue to improve therapy for CLL patients, both in the relapsed and front line settings.
Despite the outstanding efficacy observed with the novel agents, however, patients do relapse during treatment and some patients fail to respond. Progress has been made to understand the mechanisms by which patients relapse after ibrutinib therapy, and similar strategies are currently being undertaken with other novel therapies. Understanding these distinct mechanisms has the potential to lead to further targeted therapies to combat resistance, as well as the development of rational combinations to prevent the development of resistance in highrisk patients. Additionally, there are patients who do not tolerate these therapies, and work is ongoing to define risk factors for toxicity and outcomes in these patients. In this review, we will discuss the current data with targeted therapies in the treatment of relapsed CLL, mechanisms of resistance that have been identified or hypothesized, and potential strategies to treat and prevent resistance. Although there are many targeted agents coming forward, this review will focus on the currently Food and Drug Administration (FDA) approved kinase inhibitors ibrutinib
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Efficacy of Targeted therapies Approved for CLL or in Late Stage Clinical Studies
Idelalisib is an orally bioavailable, reversible, p110 delta isoform specific phosphoinositide-3 kinase (PI3K) inhibitor. Because the delta isoform is specific for B lymphocytes, this agent has selective effects on the CLL cells with relative sparing of other hematopoietic cells. It potently inhibits PI3K signaling and can block the protective effects of the CLL microenvironment in vitro. 7 It is currently FDA approved in combination with rituximab for the treatment of relapsed/refractory CLL. In Phase I study of the single agent, 72% of patients achieved an objective response, with a median PFS of 15.8 months. When focusing only on patients receiving a biologically effective dose, the PFS was 32 months. Median overall survival has not been reached, with a 36 month OS of 75%. 8 The definitive Phase III study of the idelalisib plus rituximab regimen studied this combination versus placebo plus rituximab in 220 patients. 9 At the second interim analysis, the addition of idelalisib led to an ORR of 77% (vs 15% with rituximab plus placebo), and a 12 month PFS of 66%.
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Ibrutinib is an orally bioavailable, selective, irreversible inhibitor of Bruton agammaglobulinemia Tyrosine Kinase (BTK). Both in vitro and in patients, ibrutinib has been shown to potently inhibit BCR signaling, prevent lymphocyte adhesion and homing, and inhibit protective effects of the microenvironment.
for ofatumumab vs not reached for ibrutinib) and overall survival (OS) (12-month estimates:
81% for ofatumumab, 90% for ibrutinib) were significantly improved with ibrutinib. 16 A phase II study was also conducted specifically in patients with TP53 aberrations who could have either treatment-naïve or relapsed disease. The cumulative incidence of progression at 24 months was 9% for previously untreated and 20% for previously treated patients. Estimated OS at 24 months 84% for previously untreated, and 74% for previously treated patients. 17 These data,
while not directly comparable to other trials, do suggest that patients with TP53 abnormalities may have inferior prognosis, although the contribution of karyotypic complexity in this series is unknown.
Venetoclax is an orally bioavailable, selective inhibitor of BCL2. It is a BH3 mimetic which acts similarly to the BH3-only proteins which antagonize BCL2 and its pro-survival family members.
(reviewed in 18 ) It is not currently FDA approved, but is being tested in late stage clinical studies in CLL. In Phase I study with a median follow-up of 15 months, the ORR was 77%, with a high complete response (CR) rate of 23%. Estimated median PFS is 18 months. 19 In combination with rituximab, at a median follow-up of about 7 months, the ORR was 88%, with 6 patients experiencing disease progression. This drug has been shown in clinical studies to induce minimal residual disease negative CRs, which are generally not seen with PI3K and BTK inhibitors.
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Mechanism of Resistance to Targeted Therapies
As targeted therapies have become more established in cancer therapy, so has our understanding that these agents have unique mechanisms of resistance compared with chemotherapy. In hematologic malignancies, imatinib for chronic myelogenous leukemia (CML)
was the first kinase inhibitor in widespread use. Figure 1A .
Since it appears that most CLL progressions on ibrutinib are the result of mutations in BTK or PLCγ2, a critical question is whether these mutations are present at baseline or acquired during therapy. Computational evolutionary models suggest that resistance mutations should be present prior to ibrutinib administration, 36 however, this has not yet been proven in patients. In both reports of ibrutinib-resistance due to BTK or PLCγ2 mutations, deep sequencing of the peripheral blood was performed at baseline, and no mutations were identified. 31 34 As well, a separate group performed deep sequencing in a cohort of 613 ibrutinib-naïve patients and found no mutations in BTK at C481. 37 While these data suggest that BTK C481 mutations are not commonly found in the peripheral blood, further study will need to be performed to determine whether these mutations are present in very small clones or in alternative niches. Mechanisms of resistance to idelalisib have not yet been described in CLL, although work is ongoing in this area, and predicted mechanisms of resistance and potential alternative targets can be found in Figure 1B . Because idelalisib selectively targets p110δ (encoded by PIK3CD), one likely resistance mechanism is up-regulation of either PIK3CD or an alternative class 1A PI3K, either PIK3CA or PIK3CB. In mantle cell lymphoma, it has been shown in vitro that higher ratio of PIK3CA: PIK3CD mRNA in cell lines predicts resistance to selective p110δ inhibition.
45
In a breast cancer cell line where PIK3CA was mutated, resistance to a PI3Kα inhibitor was mediated by upregulation of PIK3CA, so that PI3K function was maintained even with normally saturating concentrations of the inhibitor.
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Other preclinical studies primarily with p110α inhibitors in breast cancer models have noted other potential resistance mechanisms outside of the drug target, including MYC amplification. 47 Whether these mechanisms will be relevant to CLL remains to be seen.
Resistance mechanisms to venetoclax as well have not yet been described in CLL patients.
Predicted mechanisms and potential alternative targets can be found in Figure 1C . Drug discontinuation may discourage the development of resistance by eliminating the selective pressure of the drug, and would be very appealing in terms of toxicity and cost.
For idelalisib, ibrutinib, and venetoclax, combination studies in CLL are completed or ongoing, and presented and published outcomes from these trials can be found in Table 1 . With idelalisib, it seems that combination therapy may increase response rates over those published for single agent therapy. Increases in PFS are difficult to determine given the relatively short follow-up in these trials. For ibrutinib, combination studies have been encouraging, but response durations at this point do not appear to be different from those seen with single agent ibrutinib, potentially because only certain patients benefit from combinations.
Combinations with chemotherapy or chemoimmunotherapy are appealing because of the prospect of attainment of deeper remissions. However, it has not yet been shown with idelalisib, ibrutinib, or venetoclax that response duration or survival are correlated with attainment of a CR. In the CLL population which is predominantly elderly, it may be prudent to explore additional combinations with less toxic therapies until it is determined that there is a 
Conclusions
With the advent of many exciting and effective novel therapies for CLL comes the challenge of managing resistant disease. We expect that these drugs are improving the lifespan (and quality of life) of our CLL patients, however, resistant disease has been difficult to treat with standardly available therapies. With ibrutinib, despite the relatively low number of patients who have relapsed, a mechanism of relapse has been identified which makes it easier to determine rational combinations and salvage therapies. As more patients are treated and more relapse after idelalisib and venetoclax, it will be important to study mechanisms of resistance associated with these agents in patients as well. As well, as these agents move into front-line therapy, it will be important to determine whether similar mechanisms and trends of resistance exist.
It is tempting to believe that the challenge of refractory CLL has been effectively managed with the introduction of these oral agents, however, the disease remains incurable. As patients are treated for longer periods of time with these agents, and as increasing numbers of patients are being treated outside of clinical trials, we are likely to see the incidence of relapse increase.
Disease and patient related characteristics that predict relapse to these agents remains an area of active investigation, and as it becomes more clear which patients are likely to relapse, and conversely, which patients are not likely to relapse, we will be better able to determine which patients should be preferentially referred for clinical trials investigating combinations and novel agents. As well, clinicians and scientists will need to continue to work together to develop 1 5 rational salvage and combination therapies with these agents that can then be tested in clinical studies of patients at high risk to fail standard therapy with kinase inhibitors.
Despite these challenges, this remains a hopeful time in CLL therapy, with novel agents recently FDA approved and additional promising agents on the horizon. As well, unprecedented advances in our understanding of disease biology are uncovering other potential targets in this disease and others. Moving from the era of chemotherapy toward an era of patient-friendly novel agents represents a dramatic improvement in the life of our CLL patients, and brings us a step closer to cure of this disease.
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